文献速递胸部肿瘤妇科肿瘤消化系统肿瘤

抗间皮素抗体偶联药物Anetumab Ravtansine首次人体I期剂量递增与扩展研究

First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
PubMed 文献 · J Clin Oncol · 2020-03-26

该I期开放标签多中心研究评估了抗间皮素抗体偶联药物anetumab ravtansine在148例晚期/转移性实体瘤患者中的安全性、药代动力学和临床活性。最大耐受剂量为6.5 mg/kg每3周一次或2.2 mg/kg每周一次,常见药物相关不良事件包括疲劳、恶心、腹泻等,无药物相关死亡。148例患者中1例完全缓解、11例部分缓解、66例疾病稳定,在高剂量间皮素表达患者中观察到临床活性。

要点

  • 最大耐受剂量为6.5 mg/kg每3周一次或2.2 mg/kg每周一次。
  • 常见药物相关不良事件包括疲劳、恶心、腹泻、厌食、呕吐、周围感觉神经病和角膜炎/角膜病变。
  • 148例患者中1例完全缓解、11例部分缓解、66例疾病稳定。

核心结论

  • Anetumab ravtansine在经重度治疗的间皮素表达实体瘤患者中表现出可控的安全性和有利的药代动力学特征,并具有令人鼓舞的初步抗肿瘤活性。

研究设计与样本

  • I期开放标签多中心剂量递增和剂量扩展研究,纳入148例成人多种实体瘤患者。
  • 扩展阶段6个队列纳入晚期复发性卵巢癌或恶性间皮瘤患者,分别接受最大耐受剂量每3周一次、1.8 mg/kg每周一次和2.2 mg/kg每周一次。

主要发现

  • 最大耐受剂量为6.5 mg/kg每3周一次或2.2 mg/kg每周一次。
  • 常见药物相关不良事件为疲劳、恶心、腹泻、厌食、呕吐、周围感觉神经病和角膜炎/角膜病变,无药物相关死亡。
  • 药代动力学呈剂量比例,平均半衰期为5.5天。
  • 148例患者中1例完全缓解、11例部分缓解、66例疾病稳定。
  • 在临床活动患者中检测到高水平肿瘤间皮素表达。

关键数值与推荐

  • 剂量递增队列给药范围为0.15-7.5 mg/kg每3周一次。
  • 扩展队列给药方案包括最大耐受剂量每3周一次、1.8 mg/kg每周一次和2.2 mg/kg每周一次。
  • 最大耐受剂量为6.5 mg/kg每3周一次或2.2 mg/kg每周一次。
  • 平均半衰期为5.5天。

临床怎么用

  • 研究结果确定了anetumab ravtansine在II期研究中的推荐剂量、给药方案和患者人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This phase I study, which to our knowledge is the first-in-human study of this kind, investigates the safety, tolerability, pharmacokinetics, and clinical activity of anetumab ravtansine, an antibody-drug conjugate of anti-mesothelin antibody linked to maytansinoid DM4, in patients with advanced, metastatic, or recurrent solid tumors known to express the tumor-differentiation antigen mesothelin. PATIENTS AND METHODS: This phase I, open-label, multicenter, dose-escalation and dose-expansion study of anetumab ravtansine enrolled 148 adult patients with multiple solid tumor types. Ten dose-escalation cohorts of patients with advanced or metastatic solid tumors (0.15-7.5 mg/kg) received anetumab ravtansine once every 3 weeks, and 6 expansion cohorts of patients with advanced, recurrent ovarian cancer or malignant mesothelioma received anetumab ravtansine at the maximum tolerated dose once every 3 weeks, 1.8 mg/kg once per week, and 2.2 mg/kg once per week. RESULTS: Forty-five patients were enrolled across the 10 dose-escalation cohorts. The maximum tolerated dose of anetumab ravtansine was 6.5 mg/kg once every 3 weeks or 2.2 mg/kg once per week. Thirty-two patients were enrolled in the 6.5 mg/kg once-every-3-weeks, 35 in the 1.8 mg/kg once-per-week, and 36 in the 2.2 mg/kg once-per-week expansion cohorts. The most common drug-related adverse events were fatigue, nausea, diarrhea, anorexia, vomiting, peripheral sensory neuropathy, and keratitis/keratopathy. There were no drug-related deaths. Anetumab ravtansine pharmacokinetics were dose proportional; the average half-life was 5.5 days. Among 148 patients with mesothelioma or ovarian, pancreatic, non-small-cell lung, and breast cancers, 1 had a complete response, 11 had partial responses, and 66 had stable disease. High levels of tumor mesothelin expression were detected in patients with clinical activity. CONCLUSION: Anetumab ravtansine exhibited a manageable safety and favorable pharmacokinetic profile with encouraging preliminary antitumor activity in heavily pretreated patients with mesothelin-expressing solid tumors. The results allowed for the determination of recommended doses, schedules, and patient populations for anetumab ravtansine in phase II studies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hassan R, Blumenschein GR, Moore KN, et al. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. J Clin Oncol. 2020. PMID: 32213105. doi:10.1200/JCO.19.02085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。